US/UK/Canada

Share

About Us

Mertiva AB (former Diamyd Medical) primarily consists of holdings in liquid assets and holdings in Protein Sciences Corporation and Mercodia AB. Mertiva (former Diamyd Medical) shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink OTC Markets and the Bank of New York Mellon (PAL).

Pick a time period -
Tags ( Active)

Diamyd Medical reports results from Phase II study in cancer pain

Diamyd Medical AB reports that a Phase II study evaluating the Company’s drug candidate NP2 Enkephalin did not meet its primary objective of reducing pain in subjects with severe intractable cancer pain. The treatment was however well tolerated, confirming the safety of the Company’s NTDDS technology.The purpose of the randomized, double-blind, and placebo-controlled Phase II study is to evaluate the effect of intradermal injection of NP2 Enkephalin on pain reported by subjects suffering from severe intractable pain due to cancer, as well as to confirm the safety of the treatment. The study

Diamyd Medical's Phase II study in cancer pain fully recruited

The last study participant has been recruited to Diamyd Medical’s Phase II study in which cancer pain is treated with the drug candidate NP2 Enkephalin. The study is thus fully enrolled and results are expected to be reported in five to seven weeks.The purpose of the Phase II study is to evaluate NP2 Enkephalin for the treatment of severe and chronic cancer pain. It is the first sizeable and placebo-controlled clinical trial of a drug candidate based on Diamyd Medical’s patented Nerve Targeting Drug Delivery System, a unique technology for delivery of therapeutics directly to the nervous

Diamyd results from Phase I clinical trial in cancer pain published in Annals of Neurology

Diamyd Medical´s Phase I clinical trial results evaluating the safety and efficacy of the candidate drug NP2 Enkephalin to treat intractable cancer pain has been published in the medical journal Annals of Neurology.The publication, entitled “Gene Therapy for Pain: Results of a Phase I Clinical Trial” details the results of Diamyd’s Phase I dose-escalation clinical trial of NP2 Enkephalin through the four month evaluation period. The paper is accepted for publication in the medical journal Annals of Neurology and is available online as a pre-print. The study was designed to provide an

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media